Download PDF
Thromb Haemost 2022; 122(01): 163-170
DOI: 10.1055/s-0041-1741072
Editors' Choice

Thrombosis and Haemostasis 2021 Editors' Choice Papers

Christian Weber
1   Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany
2   German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany
3   Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, The Netherlands
,
Anne Rigby
1   Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany
,
Gregory Y. H. Lip 
4   Liverpool Centre for Cardiovascular Science, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom
5   Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

This year's Editor's Choice highlights the 2021 manuscripts published in Thrombosis and Haemostasis and its open access companion journal TH Open that found most resonance within our academic community. As in the precedent year, the 2021 COVID-19 pandemic situation has dictated the pace and direction of our research and clinical management efforts which, although not exclusively, is well reflected by this years' Editor's Choice contents.[1] [2] [3] [4]

At the end of 2020, we published a Theme Issue dedicated to COVID-19 as a guide to better comprehend newly identified vascular and inflammatory mechanistic aspects of the disease,[5] its hypercoagulation state,[6] and clinical implications for vascular patients with COVID-19.[7] [8] To address the rapidly evolving situation and following a first consensus paper,[9] we were pleased to publish an interesting discussion manuscript by the VAS investigators on the need for a more integrated and global strategy to COVID-19, providing a useful overview of public health approaches consideration and the next steps necessary to best manage the pandemic.[10] While research efforts throughout 2020 focused on characterizing the coagulation abnormalities observed in COVID19 patients giving cues to the next clinical approaches to adopt, the results from such strategies mostly came out in the following year 2021.



Publication History

Received: 02 December 2021

Accepted: 02 December 2021

Article published online:
17 January 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Lip GYH, Rigby A, Weber C. A Toast to the Last Decade and a Very Happy 2020 from Thrombosis and Haemostasis!. Thromb Haemost 2020; 120 (01) 1-4
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Lip GYH, Rigby A, Weber C. Looking Back on 2020, Looking Forward to 2021. Thromb Haemost 2021; 121 (01) 1-3
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Weber C, Rigby A, Lip GYH. Thrombosis and Haemostasis 2019 Editor's Choice Papers. Thromb Haemost 2020; 120 (01) 184-190
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Weber C, Rigby A, Lip GYH. Thrombosis and Haemostasis 2020 Editors' Choice Papers. Thromb Haemost 2021; 121 (01) 109-114
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Gencer S, Lacy M, Atzler D, van der Vorst EPC, Döring Y, Weber C. Immunoinflammatory, thrombohaemostatic, and cardiovascular mechanisms in COVID-19. Thromb Haemost 2020; 120 (12) 1629-1641
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Katneni UK, Alexaki A, Hunt RC. et al. Coagulopathy and thrombosis as a result of severe COVID-19 infection: a microvascular focus. Thromb Haemost 2020; 120 (12) 1668-1679
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Schulman S, Hu Y, Konstantinides S. Venous thromboembolism in COVID-19. Thromb Haemost 2020; 120 (12) 1642-1653
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Waite AAC, Hamilton DO, Pizzi R, Ageno W, Welters ID. Hypercoagulopathy in severe COVID-19: implications for acute care. Thromb Haemost 2020; 120 (12) 1654-1667
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Gerotziafas GT, Catalano M, Colgan M-P. et al; Scientific Reviewer Committee. Guidance for the management of patients with vascular disease or cardiovascular risk factors and COVID-19: position paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. Thromb Haemost 2020; 120 (12) 1597-1628
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Gerotziafas GT, Catalano M, Theodorou Y. et al; Scientific Reviewer Committee. The COVID-19 pandemic and the need for an integrated and equitable approach: an international expert consensus paper. Thromb Haemost 2021; 121 (08) 992-1007
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Billett HH, Reyes-Gil M, Szymanski J. et al. Anticoagulation in COVID-19: effect of enoxaparin, heparin, and apixaban on mortality. Thromb Haemost 2020; 120 (12) 1691-1699
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Di Castelnuovo A, Costanzo S, Antinori A. et al. Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicenter Italian CORIST Study. Thromb Haemost 2021; 121 (08) 1054-1065
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Gonzalez-Ochoa AJ, Raffetto JD, Hernández AG. et al. Sulodexide in the treatment of patients with early stages of COVID-19: a randomized controlled trial. Thromb Haemost 2021; 121 (07) 944-954
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Patell R, Chiasakul T, Bauer E, Zwicker JI. Pharmacologic thromboprophylaxis and thrombosis in hospitalized patients with COVID-19: a pooled analysis. Thromb Haemost 2021; 121 (01) 76-85
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Bikdeli B, Talasaz AH, Rashidi F. et al. Intermediate-dose versus standard-dose prophylactic anticoagulation in patients with COVID-19 admitted to the intensive care unit: 90-day results from the INSPIRATION randomized trial. Thromb Haemost 2021; DOI: 10.1055/a-1485-2372.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Cohen SL, Gianos E, Barish MA. et al; Northwell Health COVID-19 Research Consortium. Prevalence and predictors of venous thromboembolism or mortality in hospitalized COVID-19 patients. Thromb Haemost 2021; 121 (08) 1043-1053
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Goldin M, Giannis D, Diab W. et al. Treatment-dose LMWH versus prophylactic/intermediate dose heparins in high-risk COVID-19 inpatients: rationale and design of the HEP-COVID trial. Thromb Haemost 2021; 121 (12) 1684-1695
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Spyropoulos AC, Goldin M, Giannis D. et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern Med 2021; 181 (12) 1612-1620
    CrossrefPubMedGoogle Scholar
  • 19 Fumagalli S, Trevisan C, Del Signore S. et al. COVID-19 and atrial fibrillation in older patients: does oral anticoagulant therapy provide a survival benefit?—an insight from the GeroCovid Registry. Thromb Haemost 2021; DOI: 10.1055/a-1503-3875.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Mycroft-West CJ, Su D, Pagani I. et al. Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the Spike S1 receptor-binding domain with heparin. Thromb Haemost 2020; 120 (12) 1700-1715
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Lippi G, Favaloro EJ. D-dimer is associated with severity of coronavirus disease 2019: a pooled analysis. Thromb Haemost 2020; 120 (05) 876-878
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Valerio L, Ferrazzi P, Sacco C. et al; Humanitas COVID-19 Task Force. Course of D-dimer and C-reactive protein levels in survivors and nonsurvivors with COVID-19 pneumonia: a retrospective analysis of 577 patients. Thromb Haemost 2021; 121 (01) 98-101
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Sjöström A, Wersäll JD, Warnqvist A. et al. Platelet count rose while D-dimer levels dropped as deaths and thrombosis declined—an observational study on anticoagulation shift in COVID-19. Thromb Haemost 2021; 121 (12) 1610-1621
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Bauer W, Galtung N, Neuwinger N. et al. A matter of caution: coagulation parameters in COVID-19 do not differ from patients with ruled-out SARS-CoV-2 infection in the emergency department. TH Open 2021; 5 (01) e43-e55
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Chaudhary R, Kreutz RP, Bliden KP, Tantry US, Gurbel PA. Personalizing antithrombotic therapy in COVID-19: role of thromboelastography and thromboelastometry. Thromb Haemost 2020; 120 (11) 1594-1596
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Hammer S, Häberle H, Schlensak C. et al. Severe SARS-CoV-2 infection inhibits fibrinolysis leading to changes in viscoelastic properties of blood clot: a descriptive study of fibrinolysis in COVID-19. Thromb Haemost 2021; 121 (11) 1417-1426
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Słomka A, Kowalewski M, Żekanowska E. Hemostasis in coronavirus disease 2019-lesson from viscoelastic methods: a systematic review. Thromb Haemost 2021; 121 (09) 1181-1192
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Hardy M, Michaux I, Dive A, Lecompte T, Mullier F. Could daily monitoring of fibrin related markers help suspect a thrombotic event in COVID-19 patients? A prospective pilot study. TH Open 2021; 5 (02) e152-e154
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Sweeney JM, Barouqa M, Krause GJ, Gonzalez-Lugo JD, Rahman S, Gil MR. Low ADAMTS13 activity correlates with increased mortality in COVID-19 patients. TH Open 2021; 5 (01) e89-e103
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Léopold V, Pereverzeva L, Schuurman AR. et al. Platelets are hyperactivated but show reduced glycoprotein VI reactivity in COVID-19 patients. Thromb Haemost 2021; 121 (09) 1258-1262
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Ghirardello S, Lecchi A, Artoni A. et al. Assessment of platelet thrombus formation under flow conditions in adult patients with COVID-19: an observational study. Thromb Haemost 2021; 121 (08) 1087-1096
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Violi F, Ceccarelli G, Loffredo L. et al. Albumin supplementation dampens hypercoagulability in COVID-19: a preliminary report. Thromb Haemost 2021; 121 (01) 102-105
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Pape A, Kielstein JT, Krüger T, Fühner T, Brunkhorst R. Treatment of a critically ill COVID-19 patient with the Seraph 100 Microbind Affinity Filter. TH Open 2021; 5 (02) e134-e138
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Elalamy I, Gerotziafas G, Alamowitch S. et al; Scientific Reviewer Committee. SARS-CoV-2 vaccine and thrombosis: an expert consensus on vaccine-induced immune thrombotic thrombocytopenia. Thromb Haemost 2021; 121 (08) 982-991
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021; 384 (22) 2092-2101
    CrossrefPubMedGoogle Scholar
  • 36 Vayne C, Nguyen TH, Rollin J. et al. Characterization of new monoclonal PF4-specific antibodies as useful tools for studies on typical and autoimmune heparin-induced thrombocytopenia. Thromb Haemost 2021; 121 (03) 322-331
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Warkentin TE. Heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia antibodies: fraternal—not identical—twins. Thromb Haemost 2021; 121 (12) 1558-1561
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Sachs UJ, Cooper N, Czwalinna A. et al. PF4-dependent immunoassays in patients with vaccine-induced immune thrombotic thrombocytopenia: results of an interlaboratory comparison. Thromb Haemost 2021; 121 (12) 1622-1627
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 von Hundelshausen P, Lorenz R, Siess W, Weber C. Vaccine-induced immune thrombotic thrombocytopenia (VITT): targeting pathomechanisms with Bruton tyrosine kinase inhibitors. Thromb Haemost 2021; 121 (11) 1395-1399
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Weber C, von Hundelshausen P, Siess W. VITT after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021; 385: 2202-2205
    CrossrefPubMedGoogle Scholar
  • 41 Harenberg J, Marchetti M, Falanga A. Acquired autoimmune hemophilia following SARS-CoV-2 vaccines: dual-drug effects on blood coagulation and the Scylla and Charybdis phenomenon. Thromb Haemost 2021; 121 (12) 1555-1557
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Farley S, Ousley R, Van Wagoner N, Bril F. Autoimmunity after coronavirus disease 2019 (COVID-19) vaccine: a case of acquired hemophilia A. Thromb Haemost 2021; 121 (12) 1674-1676
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Potpara TS, Lip GYH, Blomstrom-Lundqvist C. et al. The 4S-AF scheme (Stroke Risk; Symptoms; Severity of Burden; Substrate): a novel approach to in-depth characterization (rather than classification) of atrial fibrillation. Thromb Haemost 2021; 121 (03) 270-278
    Article in Thieme ConnectPubMedGoogle Scholar
  • 44 Chao TF, Joung B, Takahashi Y. et al. 2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary. Thromb Haemost 2021; 123 (01) 20-47
    PubMedGoogle Scholar
  • 45 Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol 2017; 14 (11) 627-628
    CrossrefPubMedGoogle Scholar
  • 46 Romiti GF, Pastori D, Rivera-Caravaca JM. et al. Adherence to the 'Atrial Fibrillation Better Care' pathway in patients with atrial fibrillation: impact on clinical outcomes-a systematic review and meta-analysis of 285,000 patients. Thromb Haemost 2021; DOI: 10.1055/a-1515-9630.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 47 Lip GYH, Ntaios G. “Novel Clinical Concepts in Thrombosis”: integrated care for stroke management-easy as ABC. Thromb Haemost 2021; DOI: 10.1055/a-1632-1777.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 48 Field M, Kuduvalli M, Torella F, McKay V, Khalatbari A, Lip GYH. Integrated care systems and the aortovascular hub. Thromb Haemost 2021; DOI: 10.1055/a-1591-8033.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 49 Sun W, Freedman B, Martinez C, Wallenhorst C, Yan BP. Atrial fibrillation detected by single time-point handheld electrocardiogram screening and the risk of ischemic stroke. Thromb Haemost 2021; DOI: 10.1055/a-1588-8867.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 50 Proietti M, Boriani G. Screening for atrial fibrillation in relation to stroke and mortality risk. Thromb Haemost 2021; DOI: 10.1055/a-1562-0747.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 51 Wallenhorst C, Martinez C, Freedman B. Risk of ischemic stroke in asymptomatic atrial fibrillation incidentally detected in primary care compared with other clinical presentations. Thromb Haemost 2021; DOI: 10.1055/a-1541-3885.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 52 Wachter R, Freedman B. Subclinical atrial fibrillation and the risk of recurrent ischemic stroke. Thromb Haemost 2021; 121 (06) 697-699
    Article in Thieme ConnectPubMedGoogle Scholar
  • 53 Kitsiou A, Rogalewski A, Kalyani M. et al. Atrial fibrillation in patients with embolic stroke of undetermined source during 3 years of prolonged monitoring with an implantable loop recorder. Thromb Haemost 2021; 121 (06) 826-833
    Article in Thieme ConnectPubMedGoogle Scholar
  • 54 Nelson AJ, Johnston BW, Waite AAC, Lemma G, Welters ID. A systematic review of anticoagulation strategies for patients with atrial fibrillation in critical care. Thromb Haemost 2021; 121 (12) 1599-1609
    Article in Thieme ConnectPubMedGoogle Scholar
  • 55 Lip GYH, Genaidy A, Tran G, Marroquin P, Estes C, Sloop S. Improving stroke risk prediction in the general population: a comparative assessment of common clinical rules, a new multimorbid index, and machine-learning-based algorithms. Thromb Haemost 2021; DOI: 10.1055/a-1467-2993.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 56 Jones NR, Crawford W, Yang Y, Hobbs FDR, Taylor CJ, Petrou S. A systematic review of economic aspects of service interventions to increase anticoagulation use in atrial fibrillation. Thromb Haemost 2021; DOI: 10.1055/a-1515-9428.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 57 Camelo-Castillo A, Rivera-Caravaca JM, Marín F, Vicente V, Lip GYH, Roldán V. Predicting adverse events beyond stroke and bleeding with the ABC-stroke and ABC-bleeding scores in patients with atrial fibrillation: the Murcia AF Project. Thromb Haemost 2020; 120 (08) 1200-1207
    Article in Thieme ConnectPubMedGoogle Scholar
  • 58 Proietti M, Rivera-Caravaca JM, Esteve-Pastor MA, Marín F, Lip GYH. Stroke and thromboembolism in warfarin-treated patients with atrial fibrillation: comparing the CHA2DS2-VASc and GARFIELD-AF risk scores. Thromb Haemost 2021; 121 (08) 1107-1114
    Article in Thieme ConnectPubMedGoogle Scholar
  • 59 de Vries TAC, Hirsh J, Xu K. et al. Apixaban for stroke prevention in atrial fibrillation: why are event rates higher in clinical practice than in randomized trials?-a systematic review. Thromb Haemost 2020; 120 (09) 1323-1329
    Article in Thieme ConnectPubMedGoogle Scholar
  • 60 Chao T-F, Guo Y. Should we adopt a standard international normalized ratio range of 2.0 to 3.0 for Asian patients with atrial fibrillation? An appeal for evidence-based management, not eminence-based recommendations. Thromb Haemost 2020; 120 (03) 366-368
    Article in Thieme ConnectPubMedGoogle Scholar
  • 61 Pandey AK, Xu K, Zhang L. et al. Lower versus standard INR targets in atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Thromb Haemost 2020; 120 (03) 484-494
    Article in Thieme ConnectPubMedGoogle Scholar
  • 62 Kim HK, Tantry US, Smith Jr SC. et al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost 2021; 121 (04) 422-432
    Article in Thieme ConnectPubMedGoogle Scholar
  • 63 Choi SY, Kim MH, Lee KM. et al. Age-dependent anticoagulant therapy for atrial fibrillation patients with intermediate risk of ischemic stroke: a nationwide population-based study. Thromb Haemost 2021; 121 (09) 1151-1160
    Article in Thieme ConnectPubMedGoogle Scholar
  • 64 Chang PY, Wang W, Wu WL. et al. Oral anticoagulation timing in patients with acute ischaemic stroke and atrial fibrillation. Thromb Haemost 2021; DOI: 10.1055/a-1669-4987.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 65 Pandey AK, Eikelboom JW. Direct oral anticoagulant dosing in extremes of body weight: time to revisit the guidelines?. Thromb Haemost 2021; 121 (02) 118-120
    Article in Thieme ConnectPubMedGoogle Scholar
  • 66 Martin AC, Thomas W, Mahir Z. et al. Direct oral anticoagulant concentrations in obese and high body weight patients: a cohort study. Thromb Haemost 2021; 121 (02) 224-233
    Article in Thieme ConnectPubMedGoogle Scholar
  • 67 Boriani G, Ruff CT, Kuder JF. et al. Edoxaban versus warfarin in patients with atrial fibrillation at the extremes of body weight: an analysis from the ENGAGE AF-TIMI 48 trial. Thromb Haemost 2021; 121 (02) 140-149
    Article in Thieme ConnectPubMedGoogle Scholar
  • 68 Edlmann E, McMahon C. Balancing risks and benefits when recommencing oral anticoagulants after major bleeding. Thromb Haemost 2021; 121 (08) 979-981
    Article in Thieme ConnectPubMedGoogle Scholar
  • 69 Milling Jr TJ, King B, Yue P. et al; ANNEXA-4 Investigators. Restart of anticoagulant therapy and risk of thrombosis, rebleeding, and death after factor Xa inhibitor reversal in major bleeding patients. Thromb Haemost 2021; 121 (08) 1097-1106
    Article in Thieme ConnectPubMedGoogle Scholar
  • 70 Douxfils J, Adcock DM, Bates SM. et al. 2021 update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost 2021; 121 (08) 1008-1020
    Article in Thieme ConnectPubMedGoogle Scholar
  • 71 Giustozzi M, Agnelli G, Del Toro-Cervera J. et al. Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis. Thromb Haemost 2020; 120 (07) 1128-1136
    Article in Thieme ConnectPubMedGoogle Scholar
  • 72 Cavallari I, Verolino G, Romano S, Patti G. Efficacy and safety of nonvitamin K oral anticoagulants in patients with atrial fibrillation and cancer: a study-level meta-analysis. Thromb Haemost 2020; 120 (02) 314-321
    Article in Thieme ConnectPubMedGoogle Scholar
  • 73 Abrahami D, Renoux C, Yin H, Fournier JP, Azoulay L. The association between oral anticoagulants and cancer incidence among individuals with nonvalvular atrial fibrillation. Thromb Haemost 2020; 120 (10) 1384-1394
    Article in Thieme ConnectPubMedGoogle Scholar
  • 74 Falanga A, Gal GL, Carrier M. et al. Management of cancer-associated thrombosis: unmet needs and future perspectives. TH Open 2021; 5 (03) e376-e386
    Article in Thieme ConnectPubMedGoogle Scholar
  • 75 Atterman A, Friberg L, Asplund K, Engdahl J. Atrial fibrillation, oral anticoagulants, and concomitant active cancer: benefits and risks. TH Open 2021; 5 (02) e176-e182
    Article in Thieme ConnectPubMedGoogle Scholar
  • 76 Cohen A, Keshishian A, Lee T. et al. Effectiveness and safety of apixaban, low-molecular-weight heparin, and warfarin among venous thromboembolism patients with active cancer: a U.S. claims data analysis. Thromb Haemost 2021; 121 (03) 383-395
    Article in Thieme ConnectPubMedGoogle Scholar
  • 77 Ageno W, Vedovati MC, Cohen A. et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thromb Haemost 2021; 121 (05) 616-624
    Article in Thieme ConnectPubMedGoogle Scholar
  • 78 Jerjes-Sánchez C, Rodriguez D, Farjat AE. et al; GARFIELD-VTE investigators. Pregnancy-associated venous thromboembolism: insights from GARFIELD-VTE. TH Open 2021; 5 (01) e24-e34
    Article in Thieme ConnectPubMedGoogle Scholar
  • 79 Lecumberri R, Jiménez L, Ruiz-Artacho P. et al; RIETE investigators. Prediction of major bleeding in anticoagulated patients for venous thromboembolism: comparison of the RIETE and the VTE-BLEED scores. TH Open 2021; 5 (03) e319-e328
    Article in Thieme ConnectPubMedGoogle Scholar
  • 80 Solari D, Alberio L, Ribi C, Grandoni F, Stalder G. Autoimmune hemolytic anemia and pulmonary embolism: an association to consider. TH Open 2021; 5 (01) e8-e13
    Article in Thieme ConnectPubMedGoogle Scholar
  • 81 Valeriani E, Di Nisio M, Riva N. et al. Anticoagulant treatment for splanchnic vein thrombosis in liver cirrhosis: a systematic review and meta-analysis. Thromb Haemost 2021; 121 (07) 867-876
    Article in Thieme ConnectPubMedGoogle Scholar
  • 82 Sokou R, Piovani D, Konstantinidi A. et al. A risk score for predicting the incidence of hemorrhage in critically ill neonates: development and validation study. Thromb Haemost 2021; 121 (02) 131-139
    Article in Thieme ConnectPubMedGoogle Scholar
  • 83 Guedeney P, Collet J-P. Antithrombotic therapy in acute coronary syndromes: current evidence and ongoing issues regarding early and late management. Thromb Haemost 2021; 121 (07) 854-866
    Article in Thieme ConnectPubMedGoogle Scholar
  • 84 Jeong Y-H, Oh J-H, Yoon H-J. et al. Pharmacodynamic profile and prevalence of bleeding episode in East Asian patients with acute coronary syndromes treated with prasugrel standard-dose versus de-escalation strategy: a randomized A-MATCH trial. Thromb Haemost 2021; 121 (10) 1376-1386
    Article in Thieme ConnectPubMedGoogle Scholar
  • 85 Liesner RJ, Abraham A, Altisent C. et al. Simoctocog alfa (Nuwiq) in previously untreated patients with severe haemophilia A: final results of the NuProtect Study. Thromb Haemost 2021; 121 (11) 1400-1408
    Article in Thieme ConnectPubMedGoogle Scholar
  • 86 Gelbenegger G, Schoergenhofer C, Knoebl P, Jilma B. Bridging the missing link with emicizumab: a bispecific antibody for treatment of hemophilia A. Thromb Haemost 2020; 120 (10) 1357-1370
    Article in Thieme ConnectPubMedGoogle Scholar
  • 87 Cortesi PA, Castaman G, Trifirò G. et al. Cost-effectiveness and budget impact of emicizumab prophylaxis in haemophilia A patients with inhibitors. Thromb Haemost 2020; 120 (02) 216-228
    Article in Thieme ConnectPubMedGoogle Scholar
  • 88 Schmitt C, Adamkewicz JI, Xu J. et al. Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia A with factor VIII inhibitors: HAVEN 1 Study. Thromb Haemost 2021; 121 (03) 351-360
    Article in Thieme ConnectPubMedGoogle Scholar
  • 89 Budnick IM, Davis JPE, Sundararaghavan A. et al. Transfusion with cryoprecipitate for very low fibrinogen levels does not affect bleeding or survival in critically ill cirrhosis patients. Thromb Haemost 2021; 121 (10) 1317-1325
    Article in Thieme ConnectPubMedGoogle Scholar
  • 90 Aliotta A, Bertaggia Calderara D, Zermatten MG, Alberio L. Sodium-calcium exchanger reverse mode sustains dichotomous ion fluxes required for procoagulant COAT platelet formation. Thromb Haemost 2021; 121 (03) 309-321
    Article in Thieme ConnectPubMedGoogle Scholar
  • 91 Ya F, Li K, Chen H. et al. Protocatechuic acid protects platelets from apoptosis via inhibiting oxidative stress-mediated PI3K/Akt/GSK3β signaling. Thromb Haemost 2021; 121 (07) 931-943
    Article in Thieme ConnectPubMedGoogle Scholar
  • 92 Belleville-Rolland T, Leuci A, Mansour A. et al. Role of membrane lipid rafts in MRP4 (ABCC4) dependent regulation of the cAMP pathway in blood platelets. Thromb Haemost 2021; 121 (12) 1628-1636
    Article in Thieme ConnectPubMedGoogle Scholar
  • 93 Hally KE, Parker OM, Brunton-O'Sullivan MM, Harding SA, Larsen PD. Linking neutrophil extracellular traps and platelet activation: a composite biomarker score for predicting outcomes after acute myocardial infarction. Thromb Haemost 2021; 121 (12) 1637-1649
    Article in Thieme ConnectPubMedGoogle Scholar
  • 94 Bouvier S, Fortier M, Vincent L. et al. NETosis markers in pregnancy: effects differ according to histone subtypes. Thromb Haemost 2021; 121 (07) 877-890
    Article in Thieme ConnectPubMedGoogle Scholar
  • 95 Locke M, Longstaff C. Extracellular histones inhibit fibrinolysis through noncovalent and covalent interactions with fibrin. Thromb Haemost 2021; 121 (04) 464-476
    Article in Thieme ConnectPubMedGoogle Scholar
  • 96 Stojkovic S, Wadowski PP, Haider P. et al. Circulating microRNAs and monocyte-platelet aggregate formation in acute coronary syndrome. Thromb Haemost 2021; 121 (07) 913-922
    Article in Thieme ConnectPubMedGoogle Scholar
  • 97 Garcia A, Dunoyer-Geindre S, Nolli S, Strassel C, Reny JL, Fontana P. miR-204-5p and platelet function regulation: insight into a mechanism mediated by CDC42 and GPIIbIIIa. Thromb Haemost 2021; 121 (09) 1206-1219
    Article in Thieme ConnectPubMedGoogle Scholar
  • 98 Moon MJ, Peter K. MicroRNAs as biomarkers for personalized antiplatelet therapy. Thromb Haemost 2021; 121 (09) 1121
    Article in Thieme ConnectPubMedGoogle Scholar
  • 99 Garcia A, Dunoyer-Geindre S, Fish RJ, Neerman-Arbez M, Reny JL, Fontana P. Methods to investigate miRNA function: focus on platelet reactivity. Thromb Haemost 2021; 121 (04) 409-421
    Article in Thieme ConnectPubMedGoogle Scholar